Literature DB >> 11371747

Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.

C Lucchinetti1, W Brück, J Noseworthy.   

Abstract

The cause of multiple sclerosis is generally considered to be entirely T cell mediated. However, recent reports of studies in a variety of animal models of inflammatory demyelinating disease, coupled with detailed pathological analysis and neuroimaging studies of multiple sclerosis patients, indicate that the events involved in the formation of the multiple sclerosis lesion may be more complicated. This complex pathogenesis is reflected in the variable response of multiple sclerosis patients to immunomodulatory therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371747     DOI: 10.1097/00019052-200106000-00002

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  20 in total

1.  Short-term stability of T1 and T2 relaxation measures in multiple sclerosis normal appearing white matter.

Authors:  Alice L W Liang; Irene M Vavasour; Burkhard Mädler; Anthony L Traboulsee; Donna J Lang; David K B Li; Alex L MacKay; Cornelia Laule
Journal:  J Neurol       Date:  2011-11-26       Impact factor: 4.849

2.  Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?

Authors:  Kerstin Hackmack; Martin Weygandt; Jens Wuerfel; Caspar F Pfueller; Judith Bellmann-Strobl; Friedemann Paul; John-Dylan Haynes
Journal:  J Neurol       Date:  2012-03-24       Impact factor: 4.849

3.  MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium.

Authors:  V Dousset; B Brochet; M S A Deloire; L Lagoarde; B Barroso; J-M Caille; K G Petry
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

Review 4.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

Review 5.  [Rituximab in treatment for neuroimmunological diseases].

Authors:  A Schröder; G Ellrichmann; G Chehab; M Schneider; R A Linker; R Gold
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

6.  Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.

Authors:  Thomas Skripuletz; Maren Lindner; Alexandra Kotsiari; Niklas Garde; Jantje Fokuhl; Franziska Linsmeier; Corinna Trebst; Martin Stangel
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

7.  P-glycoprotein acts as an immunomodulator during neuroinflammation.

Authors:  Gijs Kooij; Ronald Backer; Jasper J Koning; Arie Reijerkerk; Jack van Horssen; Susanne M A van der Pol; Joost Drexhage; Alfred Schinkel; Christine D Dijkstra; Joke M M den Haan; Teunis B H Geijtenbeek; Helga E de Vries
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

Review 8.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

9.  Peripheral third cranial nerve enhancement in multiple sclerosis.

Authors:  M Tariq Bhatti; Ilona M Schmalfuss; Lorna S Williams; Ronald G Quisling
Journal:  AJNR Am J Neuroradiol       Date:  2003-08       Impact factor: 3.825

10.  Mechanisms of primary axonal damage in a viral model of multiple sclerosis.

Authors:  Jayasri Das Sarma; Lawrence C Kenyon; Susan T Hingley; Kenneth S Shindler
Journal:  J Neurosci       Date:  2009-08-19       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.